Literature DB >> 8329643

Laparoscopic surgery and gynecologic cancer.

D Dargent1.   

Abstract

Laparoscopic surgery undoubtedly has a role in the management of gynecologic cancer. As a matter of fact, the current strategy in all fields of oncology is to select high-risk and low-risk patients. The reasoning behind such a strategy is essentially to avoid for the latter the hazards of heavy treatment and to lessen the cost-to-benefit ratio. With this in mind, the laparoscopic pelvic lymphadenectomy, which is the emblematic procedure in the field of oncologic laparoscopic surgery, appears to be very useful, but only in cases where an actual risk of lymph node involvement does exist and where it may be followed in patients with negative nodes by a less aggressive treatment. Gynecologic oncologists are the only ones who can at the same time make a diagnosis, decide which treatment may be done in the patients with negative nodes, and perform the needed operation. The disasters seen in relation to ovarian cysts demonstrate the danger that does exist if we allow oncologic laparoscopic surgery to fall into inexperienced hands.

Entities:  

Mesh:

Year:  1993        PMID: 8329643

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  3 in total

1.  Major clinical research advances in gynecologic cancer in 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Kidong Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2.

Authors:  Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

Review 3.  Endoscopic management of adnexal masses.

Authors:  L Mettler; K Semm; K Shive
Journal:  JSLS       Date:  1997 Apr-Jun       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.